Has Ronald Falcon, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,047 in general payments to Ronald Falcon, MD across 152 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ronald Falcon, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ronald Falcon, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ronald Falcon, MD

Dermatology · Long Beach, NYNPI 1801853965

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 24.6% of the total. Reporting peaked in 2019 at $1,337 and has fallen 90.4% since, to $129 in 2025. That places this record below the midpoint for dermatology clinicians in NY, where the typical reported total is $2,360.

$3,047in general payments, 2019–2025

Across 152 payments — averaging $20.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$750
Novartis$508
Lilly USA, LLC$353
Sanofi$233
Biofrontera Inc.$216
Sandoz$129
plus $858 from 18 others

What the payments were for

Food & beverage$3,047100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	36	$750
Novartis	19	$508
Lilly USA, LLC	22	$353
Sanofi	10	$233
Biofrontera Inc.	13	$216
Sandoz	11	$129
E.r. Squibb & Sons, L.L.C.	5	$118
Amgen	5	$118
Mayne Pharma Commercial LLC	4	$90
Galderma Laboratories, L.p.	4	$64
Smith+Nephew	2	$63
Incyte Corporation	2	$55
Glenmark Therapeutics Inc.	5	$51
Pfizer	2	$51
Regeneron Healthcare Solutions, Inc.	2	$42
Taro Pharmaceuticals USA, Inc.	2	$39
UCB, Inc.	1	$27
Almirall LLC	1	$24
Sun Pharmaceutical Industries Inc.	1	$24
Aclaris Therapeutics, Inc.	1	$22
Dermira, Inc.	1	$21
Mylan Pharmaceuticals Inc.	1	$18
Helsinn Therapeutics (U.S.), Inc.	1	$16
Dermavant Sciences, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

COSENTYX$113

How this compares

$3,047 in reported general payments places this provider in the 50th percentile of 1,151 dermatology providers in New York.

See all dermatology providers in New York →

Medicare billing

Part B allowed, 2024

$173,491

Medicare patients

403

Services billed

2,627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Enbrel SureclickEtanercept	13	$109,430
Ammonium Lactate	239	$5,436
Metronidazole	61	$2,948
Clobetasol Propionate	42	$2,094
Ketoconazole	142	$1,934
Clindamycin Phosphate	52	$1,875
Fluorouracil	19	$1,357
Triamcinolone Acetonide	94	$1,135
Tretinoin	13	$1,126
Mometasone Furoate	57	$915
ValacyclovirValacyclovir Hcl	31	$554
Econazole Nitrate	29	$527
Mupirocin	48	$508

Paid to pharmacies, not to this prescriber.

Other dermatology in Long Beach

Alexandra GolantNew York$3.6M
David CohenNew York$3M
Michael CameronNew York$2.6M
Saakshi KhattriNew York$2.4M
Amy WechslerNew York$2.4M
Jeffrey WeinbergKew Gardens$2.3M
Joshua ZeichnerNew York$2.1M
Russell CohenOceanside$2.1M
Jeffrey LaducaAuburn$1.9M
Emma GuttmanNew York$1.7M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →